Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.
Artificial intelligence (AI) is rapidly reshaping the landscape of leukemia diagnosis, offering new possibilities for earlier detection, more precise classification, and improved patient care, ...
Equal success was found in increasing HIV self-testing (HIVST) uptake when men who have sex with men (MSM) were using either an HIVST chatbot or HIVST online real-time support by humans (HIVST-OIC).
Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and ...
“The monoclonal antibodies rituximab, ocrelizumab, ofatumumab (Kesimpta), and ublituximab (Briumvi) provide outstanding ...
Eleanor Perfetto, PhD, explores how most favored nation policy relates to broader drug pricing and cost-effectiveness debates ...
Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion ...
Zachary Contreras from Sharp Health Plan explains how managed care organizations can support early adoption of DM-BUP to ...
Key End Points for Providers to Consider With New Multiple Myeloma Therapies: Hearn Jay Cho, MD, PhD
Hearn Jay Cho, MD, PhD, chief medical officer at the Multiple Myeloma Research Foundation, shared insights on what end points ...
While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and ...
Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...
In the KEYNOTE-B96 trial ( NCT05116189 ), weekly paclitaxel with bevacizumab and pembrolizumab (Keytruda; Merck) demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback